New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene ...
Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al. which reported that the BEACON CRC trial demonstrated a survival advantage over ...
Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et which reported that the BEACON CRC trial demonstrated a survival advantage over ...
The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does ...
CHICAGO & SHANGHAI--(BUSINESS WIRE)--JS InnoPharm Ltd initiated the JSI-1187 plus dabrafenib combination dose-escalation phase of the Phase 1 study for patients with locally advanced or metastatic ...
Braftovi plus Erbitux and FOLFIRI improved progression-free survival in untreated BRAF V600E metastatic colorectal cancer in the phase 3 BREAKWATER trial. A targeted treatment that includes Braftovi ...
Existing research appears to suggest these patients can be treated similarly to patients with other genetic subtypes of cutaneous melanomas. A new review article offers insights into patients with ...
Full approval was driven by BREAKWATER Phase III outcomes, including PFS HR 0.53 and OS HR 0.49 versus fluoropyrimidine/oxaliplatin-based chemotherapy options ± ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results